Changes in the tumor microenvironment after treatment
MPM, tumor, SD
DISEASE, TUMOR, INFILTRATION, INFILTRATE
To gain insight into the potential impact of gavo-cel therapy on the tumor microenvironment (TME), we analyzed pre-treatment and post-treatment biopsies from three patients with MPM—one patient who experienced a PR (patient 3, 64% reduction in target lesion size) and two patients with a best response of stable disease (SD) (patients 18 and 21). At baseline, the TME of the responding patient was characterized by an abundance of T cells that were clearly excluded from tumor cell nests. At 8 weeks after treatment, T cells were observed to robustly infiltrate into the tumor of this responding patient. In the two non-responders, T cells were less abundant at baseline, and levels of infiltration did not notably change after treatment (Fig. Furthermore, we also evaluated the kinetics of gavo-cel PD1 expression after infusion. For the nine patients in whom this was evaluated in a longitudinal manner, there was an increase in PD-1 expression on gavo-cel T cells after infusion, compared to the pre-infusion gavo-cel product. This increase in PD-1 expression was seen irrespective of tumor response (Extended Data Fig. 